eyes-8k_20190605.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  June 4, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.

(Exact Name of Registrant as Specified in Its Charter)

California

(State or Other Jurisdiction of Incorporation)

 

001-36747

 

 

02-0692322

 

         (Commission File Number)

(IRS Employer Identification No.)

 

 

 

12744 San Fernando Road, Suite 400
Sylmar, California 91342

 

(Address of Principal Executive Offices)

 

(818) 833-5000

(Registrant's Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

EYES

 

NASDAQ

Warrants

 

EYESW

 

NASDAQ

 

 

-1-

 

 

 

 

 

 


 

ITEM 5.07Submission of Matters to a Vote of Security Holders

 

The 2019 Annual Meeting of Shareholders of Second Sight Medical Products Inc. ("Second Sight" or "Company") was held on June 4, 2019, in Los Angeles, California. Holders of 115,704,477 shares of Second Sight's common stock were represented at the meeting in person or by proxy, constituting a quorum. The following are the voting results on each matter submitted to the shareholders of Second Sight at the annual meeting. The proposals acted upon by the shareholders are described in detail in Second Sight's Proxy Statement which was filed with the Securities and Exchange Commission on April 25, 2019.

  

Proposal 1: The shareholders elected each of the five director nominees to the Board of Directors of the Company to serve until the 2020 Annual Meeting of Shareholders or until his successor has been duly elected and qualified, as follows: 

 

Nominee

 

For

 

Withheld/

Abstentions

 

Broker

Non-Votes

Will McGuire

 

86,082,462

 

188,344

 

29,433,671

William J. Link

 

85,926,724

 

344,082

 

29,433,671

Aaron Mendelsohn

 

85,968,760

 

302,046

 

29,433,671

Gregg Williams

 

85,778,488

 

492,318

 

29,433,671

Matthew Pfeffer

 

86,064,643

 

206,163

 

29,433,671

 

Proposal 2: The shareholders approved an amendment to the Restated Articles of Incorporation to increase the authorized shares of common stock of the Company from 200,000,000 shares to 300,000,000 shares, as follows:

 

 

 

For

 

Against

 

Abstentions

 

Broker

Non-Votes

 

 

108,559,132

 

3,974,325

 

745,915

 

2,425,105

 

Proposal 3: The shareholders, on an advisory basis, ratified the appointment of Gumbiner Savett Inc. as Second Sight’s independent registered public accounting firm for the year ending December 31, 2019, as follows:

 

 

 

For

 

Against

 

Abstentions

 

Broker

Non-Votes

 

 

114,509,466

 

788,181

 

406,830

 

0

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

Date: June 5, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.

 

 

/s/ John T. Blake

By: John T. Blake

Chief Financial Officer

 

 

-2-